Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Ikkou Group CoTSE:3353 +0.53%63 EBITDA Margin % is 5.30% as of Feb. 2026, which is 21% below its 10-year median of 6.70. GuruFocus rates TSE:3353 with a GF Score™ of 63/100 and a GF Value™ of 円3,534.01 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 553 Conglomerates companies, Medical Ikkou Group Co ranks worse than 73.78% on this metric.
Medical Ikkou Group Co (TSE:3353) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medical Ikkou Group Co EBITDA Margin % Related Terms
Medical Ikkou Group Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medical Ikkou Group Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Medical Ikkou Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Ikkou Group Co EBITDA Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Medical Ikkou Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medical Ikkou Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Ikkou Group Co (TSE:3353) has a EBITDA Margin % of 5.30% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medical Ikkou Group Co and its competitors. This is 21% below median its historical median of 6.70. Over the past decade, Medical Ikkou Group Co's EBITDA Margin % has ranged from 5.40 to 9.04. According to the industry distribution chart, Medical Ikkou Group Co ranks #408 out of 553 companies in the Conglomerates industry, placing it in the top 73.8%.
Is Medical Ikkou Group Co's EBITDA Margin % too high?
Medical Ikkou Group Co's current EBITDA Margin % of 5.30% is 21% below median its 10-year median of 6.70. Over the past 10 years, this metric has ranged from a low of 5.40 to a high of 9.04. The Conglomerates industry median EBITDA Margin % is 12.24. Medical Ikkou Group Co's value of 5.30% is 56.7% below this industry median. Based on the distribution chart, Medical Ikkou Group Co ranks #408 out of 553 companies in the Conglomerates industry, which is below the industry midpoint. Overall, Medical Ikkou Group Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Ikkou Group Co's EBITDA Margin % compare to HON and MMM?
According to the Conglomerates industry distribution chart, Medical Ikkou Group Co ranks #408 out of 553 companies for EBITDA Margin %. This places Medical Ikkou Group Co in the lower half of its industry. The industry median EBITDA Margin % is 12.24. Medical Ikkou Group Co's value of 5.30% is 56.7% below this benchmark. Historically, Medical Ikkou Group Co's own EBITDA Margin % has ranged from 5.40 to 9.04 over the past decade. While the company's 10-year median is 6.70 vs. the industry median of 12.24, Medical Ikkou Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Conglomerates company?
The median EBITDA Margin % among Conglomerates companies is 12.24, based on 553 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Ikkou Group Co's current EBITDA Margin % of 5.30% is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medical Ikkou Group Co and its competitors. For the Conglomerates industry, the median EBITDA Margin % is 12.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Ikkou Group Co's current EBITDA Margin % is 5.30%, which is 21% below median its own 10-year median of 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Ikkou Group Co stock overvalued right now?
Based on GuruFocus' analysis, Medical Ikkou Group Co (TSE:3353) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,534.01, compared to a current price of 円2,841.00 — trading 19.6% below its estimated fair value. The current EBITDA Margin % is 5.30%, which is 21% below median its 10-year median of 6.70 and 56.7% below the Conglomerates industry median of 12.24. Medical Ikkou Group Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medical Ikkou Group Co (TSE:3353), the current EBITDA Margin % is 5.30% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Ikkou Group Co (TSE:3353) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Ikkou Group Co stock appears to be undervalued.
The current stock price of 円2,841.00 is trading 19.6% below its estimated GF Value™ of 円3,534.01.
GuruFocus considers Medical Ikkou Group Co to be Modestly Undervalued.
Key valuation signals for TSE:3353:
EBITDA Margin %: 5.30% (21% below median its 10-year median of 6.70)
GF Value™: 円3,534.01 vs. price of 円2,841.00 (19.6% below fair value)
Industry Position: 56.7% below the Conglomerates median (#408 of 553)
No single metric tells the full story. See the TSE:3353 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Ikkou Group Co Ltd is engaged in Dispensing pharmacy business, healthcare business, pharmaceutical wholesale business, real estate business, and investment business.
63GF Score
Get the complete analysis for TSE:3353
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3353 has been successfully added to your 
